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Abstract
Background: The aim of this study is to examine the safety and distribution of Ad-EGFP-MDR1, an adenovirus 
encoding human multidurg resistance gene (human MDR1), in the mice colon carcinoma model.
Methods: After bone marrow cells (BMCs) were infected with Ad-EGFP-MDR1, they were administered by intra bone 
marrow-bone marrow transplantation (IBM-BMT). Total adenovirus antibody and serum adenovirus neutralizing factor 
(SNF) were determined. Biodistribution of Ad-EGFP-MDR1 was detected by in situ hybridization and 
immunohistochemistry. The peripheral hematocyte white blood cell (WBC), haemoglobin (Hb), red blood cell (RBC) 
and platelet (Plt) counts were analyzed.
Results: Neither total adenovirus antibody nor SNF increased weeks after BMT. In situ hybridization and 
immunohistochemistry demonstrated concordant expression of human MDR1 and P-gp which were found in lung, 
intestine, kidney and BMCs after BMT, but not detected in liver, spleen, brain and tumor. No significant abnormality of 
the recovery hematocyte was observed on Day 30 after treatment.
Conclusion: The results indicate that IBM-BMT administration of a replication defective adenovirus is a feasible mode 
of delivery, allowing exogenous transference. The findings in this study are conducted for the future long-term studies 
of safety assessment of Ad-EGFP-MDR1.
Introduction
Colorectal cancer is one of the most commonly occurring
malignancies in the world. It is sensitive to chemotherapy
and possible to be completely remitted remission of it is
possible by surgical procedure removal, the prognosis of
a d v a n c e d  o r  r e l a p s e d  c o l o r e c t a l  c a n c e r  i s  n o t  s a t i s f a c -
tory[1]. Discovered some 40 years ago, Fluorouracil (FU)
is still the most extensively studied drug and is considered
to be the standard treatment in colorectal cancer espe-
cially in advanced cancer[2]. In recent years, 5-fluoroura-
cil (5-Fu), leucovorin, oxaliplatin and cisplatin
combination chemotherapy is one of the most effective
regimen in advanced colon cancer[3]. But the dose-limit-
ing toxicities associating with these drugs, including
nephrotoxicity, myelosuppression and neurotoxicity,
influence the therapeutic efficacy[4]. Some researchers
found that the success of high-dose chemotherapy
(HDCT) and hematopoietic stem cell transplantation in
the treatment of malignancies would achieve long term
complete responses because of the dose-response rela-
tionship. [5,6]
Our preliminary studies in mice indicated that, trans-
fection of MDR1 retroviral vectors resulted in a signifi-
cant increase in P-gp expression in murine bone marrow
cells, transplantation of which into recipients resulted in
consistently high levels of MDRl expression in developing
hematopoietic cells after treatment and protecting the
normal BMCs from the toxic effects of anticancer
drugs[7,8].
In this study, we evaluated the tissue distribution and
safety of IBM-BMT applied Ad-EGFP-MDR1 in short
term. The BMCs were infected with the adenovirus vec-
tor with multiplicity of infection (MOI) 50 in 30 μl, and
transplantated in tumor-bearing Balb/c mice. Serum total
adenovirus antibody, serum adenovirus neutralizing fac-
tor (SNF), hematological, histopathology and distribution
o f  h u m a n  M D R 1  w e r e  d e t e r m i n e d  t o  m a k e  s u r e  t h e
extent of response caused by this treatment.
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Materials and methods
Mice
Balb/c mice (female and male are half-and-half, 16 g-18 g
of weight) were purchased from animal center of
ChongQing Medical University and maintained under
specific pathogen-free conditions until use in animal
facilities. Their housing, care, diet and maintenance con-
formed to the guidelines of China, the "regulation for the
care and use of laboratory animals".
Cell lines
The murine colon carcinoma cell line CT26 and human
embryonic kidney (HEK) 293 cell lines (SIBCB, China)
were cultured at 37°C and 5% CO2 in RPMI 1640 (Gibco,
America) medium, containing 10% fetal calf serum (PAA,
Austria).
Preparation of donor BMC and IBM injection of BMCs
The BMCs were collected from the femurs and tibias of
Balb/c mice and injected via IBM, as described in[9], and
then cultured at a density of 2 × 105 cells/ml in IMDM
media supplemented with bovine serum albumin and L-
glutamine. Cultures were stimulated with a combination
of the cytokines, thrombopoietin (10 ng/ml), flt3-ligand
(10 ng/ml), stem cell factor (20 ng/ml), granulocyte col-
ony-stimulating factor (15 ng/ml), interleukin (IL)-3 (10
ng/ml) and IL-6 (25 ng/ml). (R&D, America). Cells were
populated two days after primary culture, and co-cul-
tured with Ad-EGFP-MDR1 (kindly presented by profes-
sor Tong-Chuan He, EGFP:enhanced green fluorescence
protein) (MOI 50) for two days. The cultured cells were
washed by phosphate buffered sodium (PBS) for three
times and harvested. Total RNA of cells was isolated and
qualitatively analyzed with a reverse transcription poly-
merase chain reaction (RT-PCR) kit (Takara, Japan). For
MDR1: forward primer: AAAGCTGTCAAGGAAGC-
CAA, reverse primer: ACTCCATCATCGAAACCAGC.
For beta-actin, forward primer: AAGTGTGACGTT-
GACATCCG, Reverse primer: GAAAGGGTG-
TAAAACGCAGC. Reverse transcriptase reaction was
performed with PCR conditions were as follows: 94°C for
2 min (1 cycle); followed 94°C for 20 sec, 55°C for 1 min,
72°C for 30 sec (30 cycle); followed 72°C for 10 min(1
cycle). P-gp activity was determined by using the dauno-
mycin efflux assay and detected by fluorescence micro-
scope. P-gp in BMCs was investigated by western bolt.
BMCs were washed once with PBS and lysed in lysis buf-
fer. The protein concentration was determined by BCA
protein assay (Pierce). The cellular fractions were sub-
jected to SDS-PAGE [10% (w/v)] gel. The separated pro-
teins were electroblotted on polyvinyliden difluoride
(PVDF) membranes (Millipore), which were then washed
once with Tris buffered saline containing Tween 20 (TBS-
T), and then blocked in blocking buffer for 2 h. After
washing with TBS-T, the membranes were probed with
antibodies (Santa Cruz) at a dilution of 1:1000 in TBS-T.
After three washes with TBS-T, membranes were treated
for 1 h with HRP-conjugated, indicated antibodies
diluted to 1:10,000 in TBS-T. After three washes with
TBS-T, immunoreactive protein bands were revealed
with an ECL Western blot analysis system (Bio-Rad).
Films were scanned and analyzed with Quantity One
software (Bio-Rad). In addition cell viability was assessed
with a trypan blue dye exclusion test. Cell quantification
was carried out using a haemocytometer and an optical
microscope. The successful infected BMCs with green
fluorescence were determined by flow cytometry.
The donor BMCs were injected from the femurs into
the bone marrow cavity using a microsyringe containing
the donor BMCs (2 × 106/30 μl). Anesthesia for trans-
plantation: the mice were given Sumianxin (a mixture of
xylidinothiazoline, edathamil, dihydroetorphine hydro-
chloride and haloperidol) (AMMS, China) 0.5 ml/kg via
intramuscular injection. At the end of the transplantation
the mice were observed from the anesthesia.
Experimental protocols
Mice were randomly assigned to four groups, 20 animals
in each. For establishment of tumors, Balb/c mice were
injected with 5 × 107/ml, 100 μl CT 26 cells into the right
armpit. 10 days after injection, the tumor size was
detected by ultrasound, then chemotherapy was started
with 25 mg/kg 5-FU via intraperitoneal injection once a
day for 5 days, a week constituting one therapeutic course
and with 0.02 mg/kg vincristine via intraperitoneal at the
first day of each week.
Mice in Group A were tumor-bearing and transplanted
with the transfected MDR1-BMCs via IBM-BMT
(Tumor+chemotherapy+MDR1-IBM-BMT). Mice in
Group B were tumor-bearing and transplanted untreated
BMCs via IBM-BMT (Tumor + chemotherapy + IBM-
BMT). Mice in Group C were no tumor with the MDR1-
BMCs via IBM-BMT and chemotherapy (No tumor +
chemotherapy + MDR1-IBM-BMT). Group D was pre-
pared as control, in this group PBS was used instead of
tumor xenograft, transplantation and chemotherapy (No
tumor + No tranplatation + No chemotherapy). On the
second day after the end of 5-Fu chemotherapy in the first
week, the mice were transplanted with BMCs by IBM
injections.
Posttransplantation management
75% Alcohol and gentamycin were administered to the
surgical wound everyday for one week. Each mouse was
observed once every morning throughout the transplan-
tation for changes in general appearance and behavior.
Body weights were measured twice a week. Food con-
sumption was qualitatively assessed daily for each group.
Blood samples were collected via caudal vein once pre-
treatment and on Day 1, 3, 14 and 30 posttransplantation
for analysis by automated hematology analyzer (KX-21,
Sysmex Inc, Japan).Zhao et al, Journal of Experimental & Clinical Cancer Research 2010, 29:1
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Detection of human MDR1 gene biodistribution
Mice were necropsied on Day 3, 7, 14, 21 and 30, with
three samples necropsied at one time. And the following
tissues were collected: bone marrow, brain, heart, liver,
kidneys, spleen, lungs and intestine. Tumors were also
collected from the group A and B. Tissues were taken
macroscopic examination and preserved in neutral-buff-
ered 10% formalin. After 48 hours, the tissues were
embedded in paraffin, stained with hematoxylin and
eosin, and microscopically examined. A tissue microarray
(TMA) was constructed (6 mm ×4 μm). Two duplicate
specimens from each sample were placed on the array.
Paraffin-embedded sections were stained with standard
immunohistochemical techniques as introduced in [10].
In situ hybridization experiments were carried out with
a mixture of specific digoxin-labeled oligonucleotide
anti-sense probe for the human MDR1 (TBD, China).
The MDR1 DNA probe consisted of the fragment corre-
sponding to nucleotides 514-482 of the human MDR1
mRNA (genebank accession number AF016535). ISH sig-
nals were scored with a fluorescence microscope (Olym-
pus BX51, Tokyo, Japan). In situ hybridization was
performed on paraffin-embeds tissue sections according
to the manufacturer's protocol. The positive signal for
human MDR1 was detected with fluorescein isothiocya-
nate. Consecutive tissue sections were also hybridized
with sense probe under the same conditions.
Detection of Adenovirus-specific antibody and Serum 
neutralizing factors (SNF)
Adenovirus-specific antibody levels were evaluated by
ELISA on Day 3, 7, 14 days after transplantation. Diluted
serum samples were added to 96-well microtitier plates
coated with the protein of adenovirus. Each sample had
duplicate determination, tetramethylbenzidin were
added to produce a colored reaction. The absorbance was
read at 450 nm with a reference filter of 650 nm with the
microplate reader.
To detect SNF against Ad-EGFP-MDR1, serum was
incubated at 55°C for 30 min to inactivate complement. 2
× 105/well HEK 293 cells were plated into 24-well plates
(BD, America) and incubated for four hours before sam-
ple dilution. Serum was incubated with equal volume of
Ad-EGFP-MDR1 (MOI 10) for 1 hour at 37°C. The
serum/Ad-EGFP-MDR1 mixtures were transferred onto
the HEK293 cell and incubated 4 hours, supernatant was
removed and fresh medium was added. The green fluo-
rescence of cells was measured with flow cytometry at 24
hours after incubation. [11]
Statistical analysis
Hematology and ELISA results were expressed as mean ±
standard error (S.E). Data were analyzed using unpaired
student's t-test, or one-way analysis of variance ANOVA
with SAS (Biostatistics department, Chongqing Medical
University). Significance was set at P < 0.05.
Results
The transfected BMCs and macroscopic observations
Expression of EGFP was detected by fluorescence micro-
scope to observe the infection efficiency of Ad-EGFP-
MDR1 on BMCs. The subsequent distribution of the
daunomycin was also monitored by the fluorescence
microscope. Most of daunomycin aggregated inside the
BMCs which were not infected with the adenovirus.
MDR1 could effectively express in cells infected with Ad-
EGFP-MDR1 and reduce the accumulation of daunomy-
c i n .  ( F i g u r e  1 )  M D R 1  m R N A  h i g h l y  e x p r e s s e d  i n  t h e
treated BMCs which showed a unique MDR1 specific
band compared with the untreated cells. (Figure 1) We
studied the effects of Ad-EGFP-MDR1 on BMCs. An
increase in the BMCs expression of P-gp was seen. (Fig-
ure 1) Every group of BMCs cultured was low viability
losses, maintaining cell culture viability above 88% [see
BMCs infected with Ad-EGFP-mdr1 Figure 1 BMCs infected with Ad-EGFP-mdr1. Daunomycin efflux as-
say detected by fluorescence microscope. A: BMCs incubated with Ad-
EGFP-MDR1 for 48 h expressed EGFP(green). × 400 B: Daunomycin 
(red) aggregated inside the BMCs which were not infected with the ad-
enovirus. × 400 C: Bright field images of those BMCs × 400. MDR1 
mRNA in BMCs was detected by RT-PCR. D: The expected size band of 
human MDR1 mRNA was 311 bp. The expected size band of mouse 
beta-actin was 314 bp. The expression of P-gp in BMCs was assessed 
by western blot. E: Ad-EGFP-mdr1 infection induces expression and 
production of human P-gp in BMCs. Flow cytometry determined per-
centage of green fluorescence. BMCs infected with Ad-EGFP-mdr1 
successfully would show green under fluorescence channel analyses. 
F: the background was about 0.4%. G: The infection rate of BMCs incu-
bated with Ad-EGFP-mdr1 for 48 h was about 24.3%, 1.BMCs. 2.BMCs 
incubated with Ad-EGFP-mdr1 for 48 h. 3. Positive control. M:marker.
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Additional file 1]. BMCs infected with Ad-EGFP-mdr1
successfully would show green under fluorescence chan-
n e l  a n a l y s e s  b y  f l o w  c y t o m e t r y .  T h e  i n f e c t i o n  r a t e  o f
BMCs incubated with Ad-EGFP-MDR1 was obviously
higher than that of control group. The infection rate of
BMCs incubated with Ad-EGFP-mdr1 for 48 h was about
24.3%, and the background was about 0.4%.
About 10-12 days after injection, a neoplasm size from
3 mm × 3 mm × 4 mm to 5 mm × 5 mm × 7 mm appeared
in the axillary area of mice in group A and B [see Addi-
tional file 2]. Then the mice became inactive and had
reduced food consumption 1 month after transplanta-
tion. And the relative tumor weights in group A and B
significantly increased. Two mice died in group B and one
in group A, and the remaining mice of these two groups
survived for more than 2 months.
The appearance of lung, liver and spleen changed in
group A and B at the advanced stage. The thoracic cavity
and venous drainage were compressed by the grown neo-
plasm, which led to splenomegaly, enlargement of the
liver and hydrothorax.
Histopathology
Morphology examination was performed on Day 3, 7, 14,
21, 30 after transplantation. Mice showed no significant
pathological changes in the brain, lung, heart, kidneys,
spleen, liver and intestine at the first week after posttreat-
ment. However, on Day 21 and 30, lesions including car-
diac dilatation, congested lungs and hydrothorax
occurred in mice in group A and B. At the same time,
mild hydropic degeneration was found in the centrilobu-
lar regions of liver lobules, mild lymphoid and mega-
karyocytic hyperplasia was shown in the spleen, ascites
and abnormalities of central nervous system and diges-
tive system were not manifested. Histology was normal
for mice in group C and D.
Immunobiology
The levels of adenovirus-specific antibody were mea-
sured by ELISA. Optical density (OD) of group A and C
had no significant difference with that of group B and D.
(Figure 2) [see Additional file 3] It could be inferred that
the levels of adenovirus-specific antibody of group A and
C did not increase on Day 3, 7, 14 after transplantation.
Fluorescence intensity of infected HEK 293 cells, which
was measured with a flow cytometry, was inversely pro-
portional to SNF level. The SNF could inhibit the infec-
tion efficiency of Ad-EGFP-MDR1 and result in the
reduction of the fluorescence intensity. However, almost
all samples were infected, the percentages of green fluo-
rescence (infected BMCs) were 99.21%, 99.22%, 98.65%
and 99.39% for group A to D respectively on Day 7 post-
transplantation. The background was 2.45%. (Figure 3)
[see Additional file 4] We inferred that SNF against Ad-
EGFP-MDR1 was not detected in all groups.
Tissue distribution of Ad-EGFP-MDR1
Tissue distribution of Ad-EGFP-MDR1 was assessed by
immunohistochemistry and in situ hybridization. Trans-
gene expression was detected at higher frequency in
necroscopy of the major tissue of all groups. On Day 7
after BMT, expression of human MDR1 and P-gp could
be detected in kidney, lung and intestine of mice in group
A and C (Figure 4). [see Additional file 5] And it was
higher obviously on day 14 and lower on day 30 (Figure
4), while not detected in any tissue of group B and D at
any time (Figure 5). Human MDR1 predominantly
expressed in bone marrow cells and could still be
detected on Day 30 posttreatment, but its expression was
not detected in the liver, spleen, brain and tumor tissues
in our study.
Adenovirus-specific antibody measured by ELISA Figure 2 Adenovirus-specific antibody measured by ELISA. Opti-
cal density (OD) of group A and C had no significant difference with 
that of group B and D. It could be inferred that the levels of adenovirus-
specific antibody of group A and C did not increase on Day 3, 7, 14 after 
transplantation. The error bars represent one standard deviation from 
the mean values. These results are representative of three indepen-
dent experiments.
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Hematology analysis
There were some changes in hematology parameters. In
group A and C, white blood cell (WBC) counts, haemo-
globin (Hb), red blood cell (RBC) counts and platelet (Plt)
counts decreased after 3 days of IBM-BMT. But only
WBC counts in group C at that time had statistically sig-
nificant difference compared with group D (P  <0.05).
WBC counts and Plt counts in group A increased as the
tumor's growthing. It could be inferred that the tumor
might stimulate myelopoiesis and cause a leukemoid
reaction. However, at the end of first chemotherapy they
decreased with statistical significance (P < 0.05). On Day
30 after BMT, the counts of peripheral hematocyte in
group A and C were close to that in group D, and no sig-
nificant morphological abnormality was found in the
recovering hematocyte. [see Additional file 6] It demon-
strated that the transplantation of MDR1-BMCs was able
to reconstitute the hematopoietic system.
Discussion
It was demonstrated that the efficacy of human MDR1 for
chemoprotection permitted the intensified chemother-
apy in experimental animals[12]. Retroviral vector was
SNF was detected by measuring the fluorescent intensity of  HEK293 cells using a flow cytomtry Figure 3 SNF was detected by measuring the fluorescent intensi-
ty of HEK293 cells using a flow cytomtry. A: The background was 
2.45%. The percentages of green fluorescent cells were 99.21%(B), 
99.22%(C), 98.65%(D) and 99.39%(E) for group A to D respectively on 
Day 7 after the treatment. Fluorescence intensity of infected HEK 293 
cells was inversely proportional to SNF level. SNF against Ad-EGFP-
MDR1 was not detected in all groups.
   
   
 
 
Tissue distribution of Ad-EGFP-MDR1 in group A Figure 4 Tissue distribution of Ad-EGFP-MDR1 in group A. The ex-
pression of P-gp (brown staining) in group A on Day 14 after BMT by 
immunohistochemistry. (A2, B2, C2)×400. In situ hybridization local-
ized Human MDR1 expression in the tissues of group A on Day 14 after 
BMT. (A1, B1, C1, D) MDR1 DNA was labeled with FITC (green signals). 
×1000. P-gp and MDR1 DNA predominantly expressed in intestine (A), 
lung (B), kidney (C) and the BMCs (D1), but they were not detected in 
the liver, spleen, brain and tumor tissues. Human MDR1 still could be 
detected in the BMCs in group A on Day 30 posttreatmen(D2).
   
   
   
   
Tissue distribution of Ad-EGFP-MDR1 in group B Figure 5 Tissue distribution of Ad-EGFP-MDR1 in group B. The ex-
pression of P-gp (A2, B2, C2 ×400) and MDR1 DNA (A1, B1, C1×1000)in 
group B on Day 14 after BMT were not detected in intestine, lung and 
kidney.
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used in our previous study, but in this research the
recombinant adenovirus vector was used for the reason
that retroviral vector may cause carcinogenesis[13]. It
was reported that platinum chemotherapeutic agents are
used to treat many types of cancer, but drug resistance to
platinum chemotherapy is multifactorial[14]. So vincris-
tine, which was used in chemotherapy of gastroenteric
tumor and a substrate of P-gp, was used in this study.
While a variety of models have been used to evaluate
the safety of adenovirus-mediated gene therapy[15,16],
and some of them have been clinical application[17], pre-
vious studies had demonstrated that administration of
adenovirus was associated with dose-limiting toxicity,
pathology and immunogenicity. In this study, we admin-
istered the adenovirus vector by infecting BMCs via IBM-
BMT. By in situ hybridization and immunohistochemis-
try analysis, human MDR1 and P-gp were found in lung,
intestine and kidney of both genders of colon carcinoma
mice in group A and C. The biodistribution of human
MDR1 by in situ hybridization was consistent with the
expression of P-gp.
In previous study, the concentration of adenovirus
receptor in the liver was high, so as the distribution of
adenovirus vector[18]. Some studies on the homing
behavior of hemopoietic stem cells showed that part of
the transplanted cells stayed in spleen for a time, [19]
while others reported the number of donor cells in spleen
kept at a low level at all times in nonablated mice[20]. In
our study, human MDR1 and P-gp were not detected in
liver and spleen of any group. Maybe there were not
enough niches in our study. In further research human
MDR1 would be detected by taking shorter time, such as
12 hours or 1 day after transplantation and be analyzed
through more sensitive methods.
Some study reported that systemically administered
adenovirus vector had been shown inhibition of myeloid
progenitor growth, inducing transient leucopenia and
thrombocytopenia[21]. In this study, our data of blood
cell counts did not support a role for MDR1-BMCs in
dysregulated haemopoiesis in short term posttranplanta-
tion.
It had been reported that adenovirus vectors eliciting
the humoral immune response for many years[22]. And
many factors would influence immune responses, like
route of administration, dose of vector, host and so on. In
this study, Day 7 after BMT was chosen to investigate the
humoral response after administration, because some
researchers reported that SNF increased and reached
peak levels at Day 7 after local administration[11]. Our
results showed that no SNF was detected after transplan-
tation and the levels of adenovirus-specific antibody also
had no significance among each group. It indicated that
the adenovirus vector did not have notable effect on
immune response. In some other studies, adenovirus vec-
tor were administered by intravenous injection, intra-
arterial injection or localized delivery routes[23]. Adeno-
virus was detected in the injection site or major
organs[24], proinflammatory cytokine was also detected
in the serum, and inflammatory response appeared at and
near the site of injection. Their data showed that SNF and
anti-adenovirus antibody levels had been elevated post-
administration[25,26]. We considered that these differ-
ences were caused by the differences of delivery routes.
Studies with IBM-BMT showed it induced persistent
donor specific tolerance in mice even if the radiation
doses were reduced to sublethal levels. And it was good
for allogeneic BMT, because no GVHD developed, no
graft failure occurred when the radiation dose was low,
and hemopoietic recovery was rapid[27].
Conclusions
Enhanced BMCs clearance of pharmaceuticals via P-gp
may reduce plasma concentrations and in turn the thera-
peutic efficacy of these agents. It remained technically
feasible that drug resistance gene was able to protect hae-
mopoiesis from the side effects of cytotoxin in chemo-
therapy[28]. Safety studies have arisen, and the possibility
of an adverse long-term effect of Ad-EGFP-MDR1 trans-
fer on BMCs would be an important content in the fur-
ther study. In conclusion, our result shows there has no
serious side effect of adenovirus MDR1 gene therapy in
short term, which provide useful baseline data for future
long-term studies aimed at evaluating the safety of Ad-
EGFP-MDR1.
Additional material
Additional file 1
Trypan blue dye exclusion test. BMCs inviable were dyed by trypan blue. 
Every group of BMCs cultured was low viability losses, maintaining cell cul-
ture viability above 88%. A: BMCs with Ad-EGFP-MDR1. B: BMCs with PBS
Additional file 2
Colon carcinoma detected by ultrasound. (A) The xenograft tumor in arm-
pit was detected by ultrasound after 10 days of CT26 tumor cell injection. It 
was about 3 mm × 5 mm × 5 mm. (B) The blood vessel of the neoplasm. The 
speed of arterial blood was 0.017 m/s.
Additional file 3
Summary of immunobiology evaluations of adenovirus-specific anti-
body levels by ELISA. OD of group A and C had no significant difference 
with that of group B and D. Adenovirus-specific antibody did not increased at 
3, 7, 14 days after transplatation in group A and C.
Additional file 4
SNF detected reversely with green fluorescent of HEK293. SNF on Day 
3,7,14 after transplantation was detected by measuring the fluorescent inten-
sity of HEK293 cells using a flow cytometry. SNF against Ad-EGFP-MDR1 was 
not detected in all groups.Zhao et al, Journal of Experimental & Clinical Cancer Research 2010, 29:1
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